Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Drug Action01:24

Principles of Drug Action

5.9K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.9K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nano-radiosensitizers targeting tumor radioresistance: mechanisms, rational design, and clinical prospects.

Chemical communications (Cambridge, England)·2026
Same author

DNAzyme-Enhanced CRISPR/Cas12a Cascade Enables Isothermal, One-Pot RNA Diagnostics.

ACS applied materials & interfaces·2026
Same author

Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial.

Precision radiation oncology·2026
Same author

Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort.

International journal of cancer·2026
Same author

DHA/Fe<sup>2+</sup>-doped porphyrin COFs enable ROS-amplified multimodal tumor therapy.

Chemical communications (Cambridge, England)·2026
Same author

Framework Doping Enhances COF-DNA Nanoplatforms for Dual RNA Imaging and Phototherapy.

Analytical chemistry·2026

Related Experiment Video

Updated: Jun 16, 2025

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications
14:43

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

10.8K

Dual-stimuli responsive theranostic agents based on small molecules.

Shan-Shan Xue1, Wanqi Zhu1, Yuanyuan Li1

  • 1College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Institute of Molecular and Nano Science, Shandong Normal University, Jinan 250014, P. R. China. lina@sdnu.edu.cn.

Chemical Communications (Cambridge, England)
|August 19, 2024
PubMed
Summary

Small molecule dual-stimuli responsive theranostic agents offer precise disease diagnosis and therapy. This review highlights their progress, comparing responsive groups and structures for targeted biomarker applications.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

958
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.4K

Related Experiment Videos

Last Updated: Jun 16, 2025

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications
14:43

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

10.8K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

958
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

9.4K

Area of Science:

  • Biomedical Engineering
  • Chemical Biology
  • Molecular Imaging

Background:

  • Stimuli-responsive theranostic agents combine diagnostic and therapeutic capabilities.
  • These agents can be designed to react to disease-specific biomarkers.
  • Small molecule dual-stimuli responsive agents show significant potential for advanced medical applications.

Purpose of the Study:

  • To summarize the advancements in small molecule dual-stimuli responsive theranostic agents.
  • To compare the efficacy of different responsive groups and chemical structures against various biomarkers.
  • To discuss future research directions for these agents in biological systems.

Main Methods:

  • Literature review of recent studies on small molecule dual-stimuli responsive theranostic agents.
  • Comparative analysis of agent designs based on responsive moieties and chemical scaffolds.
  • Evaluation of agent performance in diagnostic and therapeutic applications within biological contexts.

Main Results:

  • Small molecule agents demonstrate tunable responsiveness to multiple stimuli and biomarkers.
  • Diverse chemical structures and responsive groups enable tailored diagnostic and therapeutic outcomes.
  • These agents facilitate precise imaging-guided interventions in preclinical models.

Conclusions:

  • Small molecule dual-stimuli responsive theranostic agents are a promising platform for integrated diagnostics and therapeutics.
  • Further optimization of responsive groups and targeting strategies will enhance their clinical translation.
  • Continued research is essential to fully realize their potential in personalized medicine.